Denali Therapeutics Inc (NASDAQ:DNLI) insider Ryan J. Watts sold 18,333 shares of the firm’s stock in a transaction dated Monday, June 3rd. The stock was sold at an average price of $19.07, for a total value of $349,610.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of NASDAQ DNLI traded down $0.48 during trading on Wednesday, hitting $19.03. The company had a trading volume of 204,600 shares, compared to its average volume of 383,077. The company has a quick ratio of 11.55, a current ratio of 11.55 and a debt-to-equity ratio of 0.14. Denali Therapeutics Inc has a 12 month low of $12.32 and a 12 month high of $28.86. The company has a market capitalization of $1.82 billion, a P/E ratio of -48.79 and a beta of 2.28.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. The company had revenue of $4.21 million during the quarter, compared to the consensus estimate of $12.88 million. Research analysts anticipate that Denali Therapeutics Inc will post -1.48 EPS for the current year.

Several research analysts have recently commented on the company. Zacks Investment Research downgraded Denali Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. ValuEngine downgraded Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, May 28th.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlueMountain Capital Management LLC bought a new stake in Denali Therapeutics during the 1st quarter valued at approximately $26,000. Quantamental Technologies LLC bought a new stake in Denali Therapeutics during the 4th quarter valued at approximately $41,000. NumerixS Investment Technologies Inc bought a new stake in Denali Therapeutics during the 1st quarter valued at approximately $60,000. Acadian Asset Management LLC bought a new stake in Denali Therapeutics during the 1st quarter valued at approximately $114,000. Finally, Legal & General Group Plc raised its stake in Denali Therapeutics by 16.3% during the 4th quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock valued at $179,000 after purchasing an additional 1,212 shares during the period. 71.69% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of international copyright and trademark legislation. The original version of this article can be read at https://www.dailypolitical.com/2019/06/05/ryan-j-watts-sells-18333-shares-of-denali-therapeutics-inc-dnli-stock.html.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

Read More: Do Tariffs Work?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.